

TABLE OF CONTENTS

CONTENTS		Page No
	Certificates	ii
	Declaration by the Candidate	iii
	Copyright Transfer Certificate	iv
	Acknowledgements	v-vi
	Table of Contents	vii-x
	List of Figures	xi-xiv
	List of Tables	xv-xvi
	List of Abbreviations	xvii-xviii
	Preface	xix-xx
Chapter 1.	Introduction	1-11
1.1.	Introduction	1
1.2.	Natural products as a potential source of drug	2
1.3.	Challenges and approaches associated with natural products-based drug discovery	4
1.4.	LC-MS-based profiling to exploring the natural products	8
Chapter 2.	Objectives and Plan of Work	12-14
2.	Aim and objective	12
2.1.	LC-MS-based dereplication and cytotoxic evaluation of <i>A. cunninghamii</i> Gum-resin	12
2.1.1.	LC-MS-based dereplication study of <i>A. cunninghamii</i> gum-resin	12
2.1.2.	<i>In-vitro</i> cytotoxic activity of <i>A. cunninghamii</i> gum-resin	12
2.1.3.	<i>In-silico</i> study of compounds <i>A. cunninghamii</i> gum-resin	12
2.2.	LC-MS-based phytochemical investigation combined network pharmacology to evaluate the cytotoxic potential of <i>A. cunninghamii</i> leaves	12
2.2.1.	LC-MS-based phytochemical study of <i>A. cunninghamii</i> leave	12
2.2.2.	Network pharmacology approach to identify the potential cytotoxicity target	12

2.2.3.	<i>In-silico</i> study of compounds <i>A. Cunninghamii</i> leaves	12
2.2.4.	<i>In-vitro</i> cytotoxic activity of <i>A. cunninghamii</i> leaves	12
2.3.	Plan of work	13
2.3.1.	LC-MS based dereplication and cytotoxic activity evaluation of <i>A. cunninghamii</i> gum-resin.	13
2.3.2.	LC-MS based phytochemical investigation combined network pharmacology to evaluate the cytotoxic potential of <i>A. cunninghamii</i> leaves	14
Chapter 3.	Literature Review	15-23
3.	Literature Review	15
Chapter 4.	LC-MS based Dereplication and Cytotoxic Evaluation of <i>A. cunninghamii</i> Gum-resin	24-55
4.	LC-MS based dereplication and cytotoxic evaluation of <i>A. cunninghamii</i> gum-resin	24
4.1.	Introduction	24
4.1.1.	Labdane and abietane diterpenoids.	25
4.2.	Results and discussion	28
4.2.1.	Phytochemical investigation of <i>A. cunninghamii</i> gum-resins	28
4.2.2.	Structure elucidation of compounds (4.09-4.22)	31
4.2.3.	NMR and LC-MS data of mixture of cupressic acid (4.12) and pimaric acid (4.19)	40
4.2.4.	Biological activity of compounds	44
4.2.4.1.	<i>In-vitro</i> cytotoxicity screening of compounds	44
4.2.4.2.	<i>In-silico</i> investigation of compounds against EGFR and α , β -tubulin	45
4.3.	Experimental section	49
4.3.1.	General Experimental Procedures	49
4.3.2.	Plant material	50
4.3.3.	Extraction and isolations	50
4.3.4.	LC-MS analysis	50
4.3.5.	Chromatographic purification	51
4.3.6.	Cytotoxic activity (Cell viability assay)	54

4.3.7.	Molecular docking	55
Chapter 5.	LC-MS based Phytochemical Investigation Combined Network Pharmacology to Evaluate the Cytotoxic Potential of <i>A. cunninghamii</i> Mudie: Leaves	56-93
5.	LC-MS based Phytochemical Investigation Combined Network Pharmacology to Evaluate the Cytotoxic Potential of <i>A. cunninghamii</i> leaves	56
5.1.	Introduction	56
5.1.1.	SAR of biflavones	58
5.2.	Results and discussion	60
5.2.1.	Phytochemical investigation of <i>A. cunninghamii</i> leaves	60
5.2.2.	Chromatographic separation and characterization of metabolites	61
5.2.3.	LC-HRMS and database mining for identification of metabolites	62
5.2.4.	Virtual ADME screening of compound	71
5.2.5.	Network pharmacology	72
5.2.5.1.	Prediction of compound and disease targets	72
5.2.5.2.	Compound-gene pathway network	73
5.2.5.3.	Hierarchical network and synergy	75
5.2.5.4.	Protein-protein interactions	76
5.2.5.5.	KEGG pathway and gene ontology (GO)	78
5.2.6.	Computational studies	79
5.2.6.1.	Molecular docking studies of compounds with EGFR, PIK3R1 AND GSK3B	79
5.2.6.2.	Molecular dynamics simulation studies	81
5.2.7.	Biological activity of compounds	83
5.2.7.1.	MTT assay for gastric cancer	83
5.3.	Experimental section	84
5.3.1.	General Experimental Procedures	84
5.3.2.	Plant material	85
5.3.3.	Preparation of the extract	85
5.3.4.	LC-HRMS and database mining	86

5.3.5. Chromatographic purification and characterization of the secondary metabolites	86
5.3.6. Virtual ADME analysis	89
5.3.7. Network pharmacology	89
5.3.8. Prediction of the known targets	91
5.3.9. Molecular docking	91
5.3.10. Molecular dynamics simulation studies	92
5.3.11. <i>In-vitro</i> cytotoxicity study	93
Chapter 6. Conclusions and Future Prospective	94-95
References	96-113
Appendix	114-137
List of Publications	138-141